STAT1 and myeloid sarcoma: In particular, the accompanying study found MP2K1, STAT1, STAT3, TF65, and HSPB1 to be differentially phosphorylated (p<0.05 after correction for multiple hypothesis testing) in MS patients relative to the controls, confirming the differential activation of cell survival and proliferation (MAPK), and pro-inflammatory (STAT) pathways in immune cells.